Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.37 USD
Change Today -0.71 / -2.08%
Volume 361.8K
RGEN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Open
$33.51
Previous Close
$34.08
Day High
$34.61
Day Low
$33.05
52 Week High
06/29/15 - $42.48
52 Week Low
09/15/14 - $18.23
Market Cap
1.1B
Average Volume 10 Days
315.4K
EPS TTM
$0.30
Shares Outstanding
32.9M
EX-Date
--
P/E TM
110.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor and cell filtration products, which are used to increase cell growth and productivity during the fermentation step of biomanufacturing, and chromatography products for purification of biologic products. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality control test kits. Further, it has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yield during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

136 Employees
Last Reported Date: 03/17/15
Founded in 1981

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $218.7K
Chief Financial Officer
Total Annual Compensation: $150.8K
Vice President of Business Development
Total Annual Compensation: $271.0K
Senior Advisor
Total Annual Compensation: $222.1K
Senior Vice President of Research & Developme...
Total Annual Compensation: $302.0K
Compensation as of Fiscal Year 2014.

repligen corp (RGEN) Key Developments

Repligen Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year of 2015

Repligen Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $21,457,267 against $15,551,077 a year ago. Income from operations was $4,608,713 against $3,105,829 a year ago. Income before income taxes was $4,351,388 against $3,243,249 a year ago. Net income was $3,612,557 or $0.11 per basic and diluted share against $2,825,422 or $0.09 per basic and diluted share a year ago. Non-GAAP EBITDA was $5,484,299 against $4,134,313 a year ago. Operating income for the second quarter was impacted by the recognition of $0.8 million in contingent consideration expense based on the high probability of the company achieving a 2015 sales milestone for the Alternating Tangential Flow (ATF) System, as predefined in the company’s asset purchase agreement with Refine Technology, LLC.  For the six months, the company reported total revenue of $42,273,543 against $31,876,930 a year ago. Income from operations was $8,647,611 against $8,413,698 a year ago. Income before income taxes was $8,549,861 against $8,641,354 a year ago. Net income was $6,542,044 or $0.19 per diluted share against $7,102,525 or $0.22 per diluted share a year ago. Non-GAAP EBITDA was $10,806,724 against $10,337,095 a year ago. Revenue guidance for the year 2015 is $78 million to $82 million, an increase from previous guidance of $75 million to $78 million. Revenue projection for 2015 is comprised exclusively of bio-processing product sales and reflects 29% to 36% sales growth, an increase from previous guidance of 24% to 29% growth. This guidance includes an estimated negative adjustment to sales growth of approximately 8% to accommodate the impact of foreign currency translation at current exchange rates. Product gross margin for the year 2015 is expected to be 56% to 58%, consistent with previous guidance. Total income from operations for the year 2015 is expected to be $14 million to $16 million, and net income is expected to be $10 million to $12 million, consistent with previous guidance. The company expected tax rate for the full year 2015 is in that kind of range between 27% to 29%.

Repligen Corporation to Report Q2, 2015 Results on Aug 06, 2015

Repligen Corporation announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Aug 06, 2015

Repligen Corporation, Q2 2015 Earnings Call, Aug 06, 2015

Repligen Corporation, Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $33.37 USD -0.71

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGEN.
View Industry Companies
 

Industry Analysis

RGEN

Industry Average

Valuation RGEN Industry Range
Price/Earnings 100.0x
Price/Sales 15.1x
Price/Book 9.5x
Price/Cash Flow 147.4x
TEV/Sales 14.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit www.repligen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.